Brief: Ovid Therapeutics Q4 EPS USD -0.13
11/03/2025 12:00
Mar 11 (Reuters) - Ovid Therapeutics Q4 operating expenses USD 10.801 million. Q4 net income USD -9.281 million
Recent news on Ovid Therapeutics
See all newsOvid Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Ovid Therapeutics Q2 revenue beats estimates
Brief: Ovid Therapeutics Q2 EPS USD -0.08
Ovid Therapeutics Inc. expected to post a loss of 11 cents a share - Earnings Preview
Brief: Ovid Therapeutics Appoints Leading Physician-Scientist And Biotech Innovator Anna Greka, M.D., Ph.D., To Board Of Directors